Alizyme Share Discussion Threads

[silverbackalpha] 19/5/2009 11:54

It isnt good IMO.

[joeblogg1000] 19/5/2009 11:53

The best thing is for this to be taken over asap, surely Takeda or someone else must be interested as we had spike up to 17p not so long ago!!

[dunderheed] 19/5/2009 11:49

Yes and nothing different from the set of results for signed of accounts in December 2008.
They were 'materially' concerned then.
loody heel sound a bit like VOW now - that's a bit worrying!!

Yes he's dropped it in again and the messaging is not good - but at the end of the day what is good about Timiny?

For me the new staff was a more positive than negative sign - don't like how one was a bit too matey with the Tim for my liking - but also as I say - think we will hear some things on the 'corporate front sooner rather than later'!! (If my hunches are correct!)

[silverbackalpha] 19/5/2009 11:38

YES THERE IS: at the recent analyst meeting even one month ago, he said there was absolutely no chance the company would run out of cash. Now this statement. I think thats major. Even Tim taking on senior staff, doesnt feel right.

[dunderheed] 19/5/2009 11:31

Actually and not wanting to sound like VOW at all but there is absolutely nothing in here today which is different from the previous set of results?!

This is why I am further confused about VOW's selling - nothing new at all in here and in theory even with the Tak schedule for Ph III as is they should have enough cash to last until then - hence am a little surprised at his/her logic - but there you go.

I can only assume inconsistency is their middle name!! Further I can only assume it was the last cosy phone call chat where Timiny spoke in riddles and whatever VOW had thought this meant did not crystallise as he expected. ie finally got fed up with the Timiny spin lines and how they differed from real life!!

Watch out libel action coming! From one anonymous avatar to another!!

[silverbackalpha] 19/5/2009 11:17

Sold out all my shares this morning.

What a crook. Tim said at the recent results there was no risk to the company continuing to operate and now "material risks of being a going concern".

Just too many "mixed" statements.

[dunderheed] 19/5/2009 10:38

Paeff - it is pocket mony now thus may as well stay here - if it come good then great - so often I have 'traded' out of similar situations - only to find that had I left the money in and it does do some form of deal or survive - the difference is not that great anyway?!

Dont really have the time to dedicate to this level of micro-detail anyway which as I say is pocket money now after the Tim has destroyed share value - watch out libel writ coming my way!!

EDIT oh nearly forgot - sorry - would not be surprsied if a few things do 'happen' over the next few months as well!!

[silverbackalpha] 19/5/2009 10:37

Now we know what that swell in volume was the other day! LOL

[peaeff] 19/5/2009 10:35

Surely the whole point is, that until nearer the time these payments are due what is the point of leaving your money idling in this company when it is pretty certain nothing is going to happen. The time to strike is when it does happen and this company finally proves that it is capable of exisiting.

[silverbackalpha] 19/5/2009 10:27

Tim did it again!

Hows the golf?

[troutfish] 19/5/2009 10:21

VOW when you sold this moring was your judgement perhaps clouded by the expectation of using some of the proceeds to pay for a visit to the PEC?

LOL - and just as AZM look set to become profitable next year if Takeda pay them a big milestone on finishing the Phase 3 Cetilistat Japan trial in July 2010.

[silverbackalpha] 19/5/2009 10:19

It is a living disaster.

[silent cartographer] 19/5/2009 10:16

Dunders,

What's your problem? Why are you acting like a child ?

You need to grow up if you want to make a success out of investing.

[dunderheed] 19/5/2009 10:07

Yo VOW meister - no apologies for calling me a plonker about the cash situation?!
Thouight all along you wre saying thsi was an out and out good gamble and opportunity to buy in and average down?
Please just for fun - can you re-confirm that the Tim had confirmed to you guys the cash situation was fine and dandy!!
Could have sworn in a message a couple of days ago you were saying this!?

[deanroberthunt] 19/5/2009 09:58

Chronicler.....you been on the sherry.

[dunderheed] 19/5/2009 09:58

Chronicler - not in the context Timiny was using!!
He was implying this in the same refernce to deals across the portfolio - which of course he has not delievered on.
If we are all agreed that RoW is fading away or is certainly not adding any short term value - are we agreed that the Tim should go - asap!!
Irrespective of our collective povs - I think this is likely to happen sooner rather than later!!

It's good to be right!!

BOL all!

[chronicler] 19/5/2009 09:41

It was useful for Alizyme to provide that link to the Takeda site confirning Cetilistat (ATL962) ends Phase 3 in Japan in July 2010. AZM definately have enopugh cash to last until then and beyond but there should be a big milestone payment to Alizyme in 2010 when this trial ends.

Now is a good time to buy I would say.

This could finally now be "off to the races".

[dunderheed] 19/5/2009 09:35

mm - it is the repeated references to this statement that I am drawing attention to - previously these were buried away and 'hidden' - now they are being trumpeted from the ceiling so the Tim can say 'told you so'!!

VOW - so I take it by selling this morning you are admitting I was right all along and you were wrong!!
What I can't udnerstand is only up until last week you were having a go at me about the 'cash situation' - and referring to Tak time lines as optimistically as ever I have heard before!!
Surely if you have been speaking to the Tim - he has been assuring you about the cash levels being okay - but you appear to not 'trust' him now?

Please confirm matey!!

[ps0u3165] 19/5/2009 09:35

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
This study is currently recruiting participants.
Verified by Prometheus Laboratories, April 2009
First Received: May 9, 2008 Last Updated: April 22, 2009 History of Changes
Sponsored by: Prometheus Laboratories

Information provided by: Prometheus Laboratories
ClinicalTrials.gov Identifier: NCT00676832

Purpose
The purpose of this study is to determine whether COLAL-PRED is a safe and effective treatment for patients with moderate to severe ulcerative colitis.



Condition Intervention Phase
Colitis, Ulcerative
Drug: Placebo
Drug: COLAL-PRED
Phase II




Genetics Home Reference related topics: Crohn disease
MedlinePlus related topics: Ulcerative Colitis
Drug Information available for: Prednisolone Prednisolone acetate Depo-medrol Medrol veriderm Methylprednisolone Prednisolone sodium phosphate 16-Methyleneprednisolone Prednisolone Sodium Succinate Methylprednisolone Sodium Succinate Methylprednisolone hemisuccinate 6-Methylprednisolone
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis


Further study details as provided by Prometheus Laboratories:


Primary Outcome Measures:
The proportion of patients with Complete Response at Week 4 defined as a decrease from baseline in the DAI score by ≥ 30% or ≥ 3 points, and with a decrease in the rectal bleeding subscore of ≥ 1 or an absolute rectal bleeding sub-score of 0 or 1. [ Time Frame: Week 4 of the study or at time of withdrawal ] [ Designated as safety issue: No ]



Secondary Outcome Measures:
The proportion of patients in Clinical Remission defined as a DAI score of ≤ 2 points, with no-individual DAI sub-score > 1 at Week 4. Patients in remission by this definition will have a rectal bleeding DAI sub-score of either 0 or 1. [ Time Frame: Week 4 ] [ Designated as safety issue: No ]


Estimated Enrollment: 200
Study Start Date: May 2008
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Group 1: Placebo Comparator Drug: Placebo
Placebo solid capsule dosage form administered orally once daily.
Group 2: Experimental Drug: COLAL-PRED
Solid capsule dosage form administered orally once daily at doses of 40 mg, 60 mg, 80 mg, 120 mg.
Group 3: Experimental Drug: COLAL-PRED
Solid capsule dosage form administered orally once daily at doses of 40 mg, 60 mg, 80 mg, 120 mg.
Group 4: Experimental Drug: COLAL-PRED
Solid capsule dosage form administered orally once daily at doses of 40 mg, 60 mg, 80 mg, 120 mg.
Group 5: Experimental Drug: COLAL-PRED
Solid capsule dosage form administered orally once daily at doses of 40 mg, 60 mg, 80 mg, 120 mg.


Detailed Description:
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-design, dose-ranging study. Eligible patients with a DAI score of 6 to 10 (inclusive), plus endoscopic evidence of moderate to severe ulcerative colitis as assessed by flexible sigmoidoscopy, unless colonoscopy is clinically indicated, and rectal bleeding will be randomized to placebo or one of four doses of COLAL-PRED (equivalent to 40, 60, 80, or 120 mg of prednisolone).

The effectiveness and safety of COLAL-PRED will be evaluated at baseline, and after 2 weeks and 4 weeks of treatment. Additional follow-up measurements will take place 7 days post cessation of treatment.

The systemic absorption of COLAL-PRED will be determined by measuring blood levels of prednisolone, prednisolone sodium metasulfobenzoate (PMSBS) and metasulfobenzoate at Week 4.

Hypothalamic-pituitary-adrenocortical (HPA) axis response will be monitored by measuring morning serum cortisol levels at Baseline, Week 2, Week 4, and at follow-up visit and cortisol levels following adrenocorticotrophic hormone (ACTH) stimulation testing at Baseline and Week 4.

Eligibility


Ages Eligible for Study: 18 Years to 75 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

[ps0u3165] 19/5/2009 09:30

Protocol Summary
Name of Sponsor:
Takeda Pharmaceutical Company Limited
Drug Under Study (r-INN):
ATL-962
Title of Protocol:
A phase 3 confrimatory study of ATL-962
Study Number:
ATL-962/CCT-002
Phase:
Ⅲ
Study Description:
A phase 3, multicenter, randomized, stratified, placebo-controlled, double-blind, parallel group study to investigate the efficacy and safety of ATL-962 in obese patients with type 2 diabetes and dyslipidemia.
Code and name of primary active drug group：399 (agents affecting metabolism n.e.c.),
administrationᦂ6;Two ATL-962 60mg tablets will be orally administered three times daily immediately after meal, target：210 subjects
endpoint：Body weight change at the completion of treatment from baseline,
planned study duration：2008-9～2010-7
Study Design:
Multicenter, stratified, randomized, double-blind, parallel-group study
Study type:
Interventional (drug)
Study Status:
On-going
Condition or disease:
Obesity
Key Criteria for inclusion and exclusion:
Key Criteria for inclusion: The subject whose BMI is not less than 25 at the start and the end of the run-in period. The subject whose visceral fat area is not less than 100 cm2 at 8 weeks after the start of the run-in period(-4 Week). The subject who is diagnosed as type 2 diabetes mellitus and the HbA1C values are >= 6.5% and < 10.0% at the start of the run-in period. The subject who diagnosed as dyslipidemia and meet one of the following criteria for the fasting plasma lipid profile at the start of the run-in period: Hyper-LDL cholesterolemia:LDL cholesterol >= 140 mg/dL Hypo-HDL cholesterolemia:HDL cholesterol < 40 mg/dL Hypertriglyceridemia:Triglyceride >= 150 mg/dL Age：20years old or more Gender：Both
Key Criteria for exclusion: The subject who have received any anti-obesity drugs (Mazindol and/or prescribed herb medicines which are indicated as an anti-obesity drug) within 4 weeks prior to the start of the run-in period
Location of the study sites:
Japan (Multicenters)

[silent cartographer] 19/5/2009 09:04

VOW,

Might have been worth staying in as I still think there will be an offer for the company at some point.

I'm staying in purely as I'm not invested too heavily, and it's money I can afford to lose if it goes belly up, but if you had a rather large holding and felt uncomfortable with it, then I don't blame you...

Good luck.

[vow] 19/5/2009 09:01

Cheers Peaeff,

Being pro and anti isn't as black and white as everyone on here makes out, this rns tipped me over what I see as an acceptable risk so I sold, simple.

Corsondav.

See Takeda link.

Not aware of this ever being brought to our attention before, pushed the money to the limit so it is ALL about ROW now.